

Applicants: David J. Pinsky et al.
U.S. Serial No.: CPA of 09/374,586
Filed: August 13, 1999
Page 2

In The Claims

Please cancel claims 21, 25 and 26 without prejudice or disclaimer.

Please amend claims 2, 4, 8 and 17 as follows:

Sub 2
--2. (2x Amended) The method of claim 1, wherein the active polypeptide fragment of CD39 polypeptide is administered and is a truncated form of the CD39 polypeptide.--

2
--4. (Amended) The method of claim 3, wherein the CD39 polypeptide is a recombinant CD39 polypeptide having an IL-2 leader sequence.--

2
--8. (Amended) The method of claim 1, wherein the CD39 polypeptide or its fragment is administered as a composition comprising the CD39 polypeptide or its fragment and a pharmaceutically acceptable carrier.--

Sub 4
--17. (3x Amended) A method for determining whether a compound which increases ADP catabolism inhibits platelet aggregation or leukocyte accumulation and does not increase incidence of intracerebral hemorrhage, so as to treat or prevent thrombotic or ischemic disorder in a subject, comprising:

(a) administering the compound to an animal, which is a model for the thrombotic or ischemic disorder, before, concurrently with or after step (b);

Applicants: David J. Pinsky et al.
U.S. Serial No.: CPA of 09/374,586
Filed: August 13, 1999
Page 3

- Q4
- (b) inducing the thrombotic or ischemic disorder in the animal;
 - (c) measuring the stroke outcome and the incidence of intracerebral hemorrhage in the animal;
 - (d) measuring platelet or fibrin deposition or both in ischemic tissue in the animal; and
 - (e) comparing the stroke outcome and incidence of intracerebral hemorrhage and the platelet or fibrin deposition in the presence of the compound with in the absence of the compound wherein a decrease in platelet or fibrin deposition and no increase in the incidence of intracerebral hemorrhage indicates that the compound is capable of treating or preventing the thrombotic or ischemic disorder in the subject.--

Please add new claim 27:

See 27
CS
-27.

(New) A method for treating or preventing stroke in a human subject susceptible to intracranial hemorrhaging, comprising administering to the human subject an effective amount of a deletion mutant, substitution mutant, or insertion mutant of the CD39 polypeptide, which polypeptide comprises consecutive amino acids having the sequence shown in SEQ ID NO:1, so as to inhibit adenosine diphosphate-mediated platelet aggregation by increasing adenosine diphosphate